Therapeutic effects of inhaling budesonide and formoterol in stable chronic obstructive pulmonary disease

Objective To observe the benefits of therapy with inhaling of budesonide and formoterol in stable chronic obstructive pulmonary disease.Methods48 patients with stable COPD were randomly divided into trial and control groups.Baseline treatments were similar in all patients.24 patients in the trial group received budesonide and fomoterol inhalation twice a day for 12 weeks.The other 24 patients in the control group didn't inhale budesonide and formoterol.Before and after the therapeutic course,tests for lung function in patients of these two groups were examined and compared with each other.The measures included the method of standard grade of respiratory diseases questionnaire(SGRQ),6 minutes walk test(6MWT),and the proportion of hospitalized patients due to AECOPD.ResultsThe values of FEV1/FVC and FEV1/predictive value in the trial group increased in different extent than the control group(P0.05).In the trial group,the value of SGRQ became significantly lower than that the control group(P0.05).In the trial group,the proportion of hospitalized patients due to AECOPD was lower than that of the control group(P0.05).ConclusionBudesonide and fomoterol are effective bronchodaliator on improving lung function and health status in patients with stable COPD.